A host of
Now the U.S. Food and Drug Administration said today that it has taken steps to boost the supply of those cancer drugs -- Doxil, or doxorubicin hydrochloride liposome injection, and
On Doxil, the FDA plans to import temporarily a replacement drug called Lipodox to meet patient needs in coming weeks. On methotrexate, the agency expedited review of the application from the manufacturer APP Pharmaceuticals to make the necessary preservative-free drug here. Another maker,
The FDA has been working for some time to get the drug companies to notify the agency when shortages appear to be coming within six months. Officials have release draft guidance to industry on mandatory and voluntary notifications per an executive order from President Obama in October.
Since then, the publicity has produced a sixfold increase in voluntary notices of potential shortages, and the FDA said 114 of them were averted.
Doxil is used for many types of cancer, including
The shortage of methotrexate is partially attributed to the largest manufacturer, Bedford/Ben Venue, closing its plant. But there are several reasons for other shortages, including unclean plants closing, increased demand and drug companies switching to more profitable drugs.